Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement

D. Goldsmith, A. Covic, M.G. Vervloet, M. Cozzolino, I. Nistor

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)698-700
JournalNephrology, Dialysis, Transplantation
Issue number5
Publication statusPublished - 2015

Cite this